Nomifensine: effect in Parkinsonian patients not receiving levodopa.
A clinical trial using the anti-depressant nomifensine in Parkinsonism is reported. Eighteen subjects not receiving levodopa participated. The drug had a small, but significant anti-Parkinsonian effect. No troublesome side effects were encountered. In the treatment of Parkinsonism, nomifensine may be considered as an alternative to amantadine or anticholinergics, especially where depression is an added feature.
D000368:Aged; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007546:Isoquinolines / Q000627:therapeutic use*; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009627:Nomifensine / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*
D007546:Isoquinolines; D009627:Nomifensine; D007980:Levodopa